BioDelivery Sciences Revenue 2006-2021 | BDSI

BioDelivery Sciences revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
BioDelivery Sciences Annual Revenue
(Millions of US $)
2020 $156
2019 $111
2018 $56
2017 $62
2016 $16
2015 $48
2014 $39
2013 $11
2012 $55
2011 $3
2010 $3
2009 $63
2008 $0
2007 $0
2006 $0
2005 $1
BioDelivery Sciences Quarterly Revenue
(Millions of US $)
2021-06-30 $41
2021-03-31 $41
2020-12-31 $42
2020-09-30 $39
2020-06-30 $37
2020-03-31 $38
2019-12-31 $32
2019-09-30 $30
2019-06-30 $30
2019-03-31 $20
2018-12-31 $18
2018-09-30 $14
2018-06-30 $12
2018-03-31 $11
2017-12-31 $13
2017-09-30 $11
2017-06-30 $9
2017-03-31 $29
2016-12-31 $4
2016-09-30 $4
2016-06-30 $5
2016-03-31 $3
2015-12-31 $32
2015-09-30 $1
2015-06-30 $2
2015-03-31 $13
2014-12-31 $3
2014-09-30 $2
2014-06-30 $14
2014-03-31 $21
2013-12-31 $4
2013-09-30 $3
2013-06-30 $3
2013-03-31 $2
2012-12-31 $20
2012-09-30 $2
2012-06-30 $16
2012-03-31 $17
2011-12-31 $0
2011-09-30 $3
2011-06-30 $0
2011-03-31 $0
2010-12-31 $1
2010-09-30 $0
2010-06-30 $2
2010-03-31 $0
2009-12-31 $63
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
2008-12-31 $0
2008-09-30 $0
2008-06-30 $0
2008-03-31 $0
2007-12-31 $0
2007-09-30 $0
2007-06-30 $0
2007-03-31 $0
2006-12-31 $0
2006-09-30 $0
2006-06-30 $0
2006-03-31 $0
2005-12-31 $0
2005-09-30 $0
2005-06-30 $1
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.367B $0.156B
BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29